Briganix 90 mg (Brigatinib) is an advanced oral medication specifically designed for the treatment of ALK-positive non-small cell lung cancer (NSCLC) in adults. Brigatinib is a next-generation tyrosine kinase inhibitor (TKI) that targets the abnormal anaplastic lymphoma kinase (ALK) gene mutation, a key driver of cancer cell growth in some forms of lung cancer. Briganix 90 mg is especially effective…
Caboxen 20 mg , featuring the active ingredient Cabozantinib , is a cutting-edge oral medication designed to treat advanced renal cell carcinoma (RCC) and medical thyroid cancer (MTC). As part of the tyrosine kinase inhibitors (TKI) class, Caboxen targets multiple receptors involved in tumour growth, effectively slowing or stopping cancer progression. With its proven efficacy, Caboxen offers a powerful solution…
Cabozanix (Cabozantinib) is a cutting-edge oral medication designed to treat advanced stages of various cancers, including renal cell carcinoma (RCC), hepatocellular carcinoma (HCC), and medullary thyroid cancer (MTC). As a tyrosine kinase inhibitor (TKI), Cabozantinib blocks specific proteins that drive the growth and spread of cancer cells. Available in 20 mg, 60 mg, and 80 mg strengths, Cabozanix is a…
Capmaxen-200MG is a highly effective antibiotic designed to tackle many bacterial infections. With its powerful 200MG formulation, this medication is ideal for treating common infections such as respiratory tract infections, urinary tract infections, and skin infections. Capmaxen-200MG works by inhibiting bacterial growth, allowing your immune system to clear the infection and helping you feel better faster. Whether you’re…
Cerinib 150 mg contains Ceritinib, a powerful targeted therapy specifically designed for the treatment of ALK-positive non-small cell lung cancer (NSCLC). It is an oral medication used to manage advanced stages of lung cancer, particularly in patients whose cancer has spread to other parts of the body (metastatic) and who may have developed resistance to prior treatments. Ceritinib works by…
Crizocent 250mg (Crizotinib) is a highly effective targeted therapy specifically designed to treat advanced non-small cell lung cancer (NSCLC) that is ALK-positive (anaplastic lymphoma kinase) or ROS1-positive. This innovative medication works by blocking the activity of proteins (ALK and ROS1) that promote cancer cell growth, making it an essential treatment for patients with these specific genetic mutations. Crizocent is trusted…
Elopag 25mg & 50mg, powered by the active ingredient Eltrombopag, is a highly effective oral medication used to treat chronic immune thrombocytopenia (ITP), aplastic anemia, and chronic hepatitis C-related thrombocytopenia. Thrombocytopenia occurs when your platelet count is too low, leading to excessive bruising or bleeding. Elopag works by increasing platelet production, helping to restore a safe platelet level in the…
Hertinib-40mg (Neratinib) is an advanced oral medication specifically designed to treat early-stage HER2-positive breast cancer in patients who have completed prior trastuzumab-based therapy. As a targeted therapy, Hertinib-40mg works by inhibiting the HER2 protein, which is responsible for the growth and spread of cancer cells. By blocking this protein, Hertinib-40mg helps prevent cancer from returning, offering patients improved outcomes and…
Ibrucent 140 mg (Ibrutinib) is an innovative oral medication used to treat specific types of blood cancers, including Chronic Lymphocytic Leukemia (CLL), Mantle Cell Lymphoma (MCL), and Waldenström’s Macroglobulinemia (WM). Ibrutinib, the active ingredient in Ibrucent, is a Bruton’s Tyrosine Kinase (BTK) inhibitor. This targeted therapy blocks the activity of BTK proteins, which are crucial for the growth and survival…
Ibruxen Capsule 140mg, containing Ibrutinib 140mg, is a powerful oral medication for certain blood cancers. Known for its effectiveness, it primarily targets chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), and Waldenström's macroglobulinemia. Developed to inhibit Bruton's tyrosine kinase (BTK), Ibruxen helps prevent cancer cells from growing and multiplying, offering hope for those dealing with these challenging conditions.
Ivosenib 250mg (Ivosidenib 250mg) is a groundbreaking medication designed to Treatment Acute Myeloid Leukemia (AML), particularly in patients with a specific genetic mutation called IDH1. This targeted therapy offers new hope for patients whose cancer is resistant to conventional treatments, providing a highly specialized approach that can transform the course of this aggressive blood cancer.
Lenvanix (Lenvatinib) is a powerful cancer-fighting medication available in 10 mg and 4 mg doses. As a targeted therapy, Lenvanix plays a critical role in treating advanced thyroid cancer, liver cancer (hepatocellular carcinoma), and renal cell carcinoma (kidney cancer). This oral medication works by inhibiting proteins in cancer cells that promote tumour growth, helping to slow or even stop the…
